Analysts Cut Boston Scientific Ratings and Price Targets After Q3
Jefferies downgraded Boston Scientific to Hold from Buy with a $46 price target, and JPMorgan moved to Neutral from Overweight with a $46 target. Oppenheimer cut its rating to Market Perform from Outperform; RBC lowered its target to $52 from $70 and Needham to $48 from $57, while both maintained their ratings.
Following Boston Scientific's Q3 2026 earnings release, several analysts adjusted their outlooks on the company. Jefferies downgraded the stock to Hold from Buy with a $46 price target, while JPMorgan moved the stock to Neutral from Overweight, also setting a $46 target. Oppenheimer downgraded the company to Market Perform from Outperform, and RBC reduced its price target to $52 from $70 while maintaining an Outperform rating. Needham also adjusted its price target to $48 from $57 while keeping a Buy rating.
These actions reflect analyst reactions to the company's lowered full-year guidance and operational headwinds.